Research from Queen Mary University of London has identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects over 1.5 million people in the UK alone.
The research team, made up of scientists from Queen Mary University of London, the University of Manchester, Cardiff University, and Radboud University Medical Center, Nijmegen, found significantly higher levels of a protein called factor H-related protein 4 (FHR-4) in the blood of AMD patients.
Further investigation, using eye tissue donated for medical research, showed the presence of the FHR-4 protein within the macula – the specific region of the eye affected by the disease.
The results of this study open up new routes for the early diagnosis, by measuring FHR-4 levels in the blood, and suggests therapies targeting this protein could provide promising future treatment options for the disease.
The study is published today in Nature Communications.
Uncovering the genetics behind AMD
FHR-4 regulates the complement system, part of the immune system, which plays a critical role in inflammation and the body’s defence against infection.
Previous studies have linked the complement system to AMD showing that genetically inherited faults in key complement proteins are strong risk factors for the condition.
In this study, the researchers used a genetic technique, known as a genome-wide association study, to identify specific changes in the genome related to the increased levels of FHR-4 found in AMD patients.
They found higher blood FHR-4 levels were associated with changes to genes that code for proteins belonging to the factor H family, which clustered together within a specific region of the genome. The identified genetic changes also overlapped with genetic variants first found to increase the risk of AMD over 20 years ago.
Together, the findings suggest that inherited genetic changes can lead to higher blood FHR-4 levels, which results in uncontrolled activation of the complement system within the eye and drive disease.
Blood levels of FHR4 were measured in 484 patients and 522 age-matched control samples using two independent, established collections of AMD patient data. These were the Cambridge AMD study, led by Professor Anthony Moore from Moorfields Eye Hospital and UCL Institute of Ophthalmology (now at the University of California San Francisco), and Professor John Yates from Cambridge University, and the European Genetic Database (EUGENDA), led by Professor Anneke den Hollander and Professor Carel Hoyng from Radboud University Medical Center.
Step-change in understanding
There are two main types of AMD – “wet” AMD and “dry” AMD. Whilst some treatment options exist for ‘wet’ AMD, there is currently no available treatment for “dry” AMD.
Dr Valentina Cipriani, who jointly led the statistical data analysis with Dr. Laura Lorés-Motta from the Radboud University Medical Center and is an expert in ophthalmic statistical genetics at Queen Mary University of London, and member of the International AMD Genomics Consortium (IAMDGC), said: “By unveiling FHR-4 as a novel, key molecular player for AMD, our study was able to dissect further the genetic disease predisposition at the factor H region. This is one of the most established genetic associations in the field of complex genetics. We hope our findings will accelerate interest from the wider research community in the involvement of the complement system in AMD, with the ultimate goal of uncovering the role of the whole ‘complementome’ in the disease.”
Professor Simon Clark, a specialist in the regulation of the complement system in health and disease at the University of Manchester, said: “This study really is a step-change in our understanding of how complement activation drives this major blinding disease. Up until now, the role played by FHR proteins in disease has only ever been inferred. But now we show a direct link and, more excitingly, become a tangible step closer to identifying a group of potential therapeutic targets to treat this debilitating disease.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Age-related macular degeneration
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusion August 19, 2021 at 4:00 am
Exclusive Worldwide Licensing Agreement with Cella Therapeutics Adds an Array of New Chemical Entities to Visus’ Drug PipelineAgreement with DelSiTech for Sustained Drug Delivery Platform Allows Visus ...
- Genetic Mechanism Revealed of Age-Related Macular Degeneration Based on Fusion of Statistics and Machine Learning Methodon August 13, 2021 at 8:22 am
Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world which affects the quality of life for millions of elderly individuals worldwide.
- Why is Age Related Macular Degeneration Drug Market Booming Worldwide ? Know the latest trends and Top market playerson August 12, 2021 at 4:38 am
Stratagem Market Insights started a new study on the Global Age Related Macular Degeneration Drug Market, providing forecasts for the period of 2021-2027. In the study, growth opportunity for the Age ...
- Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?on August 11, 2021 at 3:25 pm
People with macular degeneration will either experience the dry (atrophic) form of macular degeneration or the wet (neovascular) form. The American Academy of Ophthalmology (AAO) reports that about 80 ...
- Age Related Macular Degeneration News and Researchon August 5, 2021 at 5:00 pm
Age-related macular degeneration (AMD) is the principal cause of vision loss in industrialised countries, with nearly 20 million people affected in Europe in 2020. Although identified as a risk ...
Go deeper with Google Headlines on:
Age-related macular degeneration
Go deeper with Bing News on:
- 5. Novartison August 23, 2021 at 5:00 am
Novartis' 12 new drugs include heavy hitters in the cell and gene therapy field such as Zolgensma, plus the company's new macular degeneration drug Beovu. The latter med was duking it out with ...
- Drs. Vadivel Ganapathy, Julian Nussbaum and Emory Patterson, Medical College of Georgia (IMAGE)on August 22, 2021 at 6:57 pm
The most common -- and under-diagnosed -- genetic disease in humans just may be a cause of the worst form of macular degeneration, Medical College of Georgia researchers report. They are pursuing a ...
- Annual eye exams essential to Veterans’ vision and eye healthon August 20, 2021 at 11:00 am
Annual eye exams essential to Veterans’ vision and eye health. Joint study shows promising results in preventing age-related blindness.
- Best Eye Vitamins – Top 13 Vision Support Supplements to Buyon August 19, 2021 at 11:32 am
It is pretty natural for the vision to decline as a person gets older. Even with glasses and contact lenses, one might struggle to see things clearly at a certain age.
- Novartis phase III trials of Beovu in diabetic macular edema shows positive resultson August 17, 2021 at 10:10 pm
Beovu has the potential to manage the disease in appropriate patients with a relaxed loading phase every six weeks, and dosing intervals as infrequent..